Company Legal Name
Latest Valuation
Founded Year
Headquarter
Caris Life Sciences provides molecular profiling services that enable personalized cancer diagnosis, treatment selection, and patient monitoring through advanced genomic testing. Founded in 2008 and headquartered in Irving, Texas, the company has established itself as a significant player in the precision oncology market by offering comprehensive tumor profiling that helps oncologists make data-driven treatment decisions. Caris leverages multi-platform molecular analysis to identify actionable biomarkers and therapeutic targets for cancer patients. The company continues to focus on expanding its molecular profiling capabilities and strengthening partnerships with healthcare providers to advance personalized cancer care and improve patient outcomes.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
